In terms of cancer-driven mutations, the HRSI group has two significant mutations, including HRAS and KLF5, while the LRSI group has three significant mutations, including ATP6V0A2, BSX, and VNN1 (Figures 6 and 7). Here, ATP6V0A2 is linked to cancer.